logo_Cystic-Fibrosis-Foundation.png

AmpliPhi has received initial funding support from Cystic Fibrosis Foundation Therapeutics, Inc. (a non-profit affiliate of the Cystic Fibrosis Foundation) to support development of AB-PA01. The company plans to evaluate AB-PA01 in aerosolized form for the treatment of lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.


logo_royal-brompton.png

AmpliPhi maintains a research collaboration agreement with the Royal Brompton Hospital. The Royal Brompton is one of the main centers for excellence in the study of Cystic Fibrosis.


logo_University-of-Leicester.png

AmpliPhi maintains a license agreement with the University of Leicester to develop a phage therapy that targets and kills all clinically relevant toxin types of C. difficile.


logo_US-Army.png

AmpliPhi holds a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research, focusing on developing and commercializing bacteriophage therapeutics to treat S. aureus, E. coli and P. aeruginosa infections.


logo_University-of-Leicester.png

AmpliPhi holds a clinical trial agreement with the University of Adelaide in conjunction with Flinders University. Our primary investigator, Dr. Peter-John Wormald, is a key opinion leader in the treatment of chronic rhinosinusitis.


logo_westmead-institute.png

AmpliPhi partnered with the Westmead Institute in an Australian grant application to identify, isolate and characterize novel and lytic phages to target both E.coli and K. pneumonia.